Clinical trial
Study of ADH-1 Given Intravenously to Patients With Solid Tumors
NCT00265057 · Adherex Technologies, Inc., Industry · Completed
Key facts
| NCT number | NCT00265057 |
|---|---|
| Title | Study of ADH-1 Given Intravenously to Patients With Solid Tumors |
| Official title | Dose Finding, Safety, Pharmacokinetic and Pharmacodynamic Study of the Vascular Targeting Agent Exherin™ (ADH-1) Administered Once Weekly in 3 Week Cycles by Intravenous Infusion in Patients With N-Cadherin Expressing, Incurable, Solid Tumors (Adherex Protocol Number AHX-01-004) |
| Lead sponsor | Adherex Technologies, Inc., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Neoplasms |
| Intervention type | Drug |
| Interventions | ADH -1 (Exherin™) |
| Start date | Jun 1, 2005 |
| Completion | Jan 1, 2008 |
| First posted | Dec 14, 2005 |
| Last update posted | Dec 28, 2010 |
| Countries | Italy, Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: